Certara
CERT
About: Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Employees: 1,546
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
65% more call options, than puts
Call options by funds: $708K | Put options by funds: $430K
24% more capital invested
Capital invested by funds: $1.21B [Q1] → $1.5B (+$295M) [Q2]
3.44% more ownership
Funds ownership: 75.74% [Q1] → 79.18% (+3.44%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
4% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 47
2% less funds holding
Funds holding: 239 [Q1] → 234 (-5) [Q2]
18% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 90
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
UBS
Dan Leonard
|
$15
|
Buy
Maintained
|
7 Aug 2025 |
|
Keybanc
Scott Schoenhaus
|
$15
|
Overweight
Maintained
|
14 Jul 2025 |
|
Morgan Stanley
Sean Laaman
|
$16
|
Equal-Weight
Assumed
|
3 Jul 2025 |
Financial journalist opinion
Based on 5 articles about CERT published over the past 30 days
